Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691197 · ClinicalTrials.gov registry record · Phase 2
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
A Phase 2 study of Ametropia, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
- 1
- Study location
NCT00691197 is a Phase 2 study of Ametropia that has completed, run by Allergan. The registered enrollment target is 246 participants, above the 106-participant average among 5 other Ametropia trials with a reported enrollment target (132% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00691197, a Phase 2 study of Ametropia, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
- 1
- Study location
Study Summary
Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
Conditions Studied
Interventions
- DEVICE Carboxymethylcellulose sodium and Glycerin
- DEVICE Carboxymethylcellulose sodium
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691197
The ClinicalTrials.gov registry entry for NCT00691197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 5 other Ametropia trials with a reported enrollment target (132% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ametropia appearing as the primary indexed condition, and to 2 interventions - of which Carboxymethylcellulose sodium and Glycerin is the first listed.
NCT00691197 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00691197 about?
NCT00691197 is a clinical study titled "Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear". Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
What is the current status of trial NCT00691197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2008-03. Estimated completion is 2008-10.
What conditions does trial NCT00691197 study?
This clinical trial studies the following conditions: Ametropia.
What interventions are being tested in trial NCT00691197?
The interventions under investigation include: Carboxymethylcellulose sodium and Glycerin (DEVICE), Carboxymethylcellulose sodium (DEVICE).
Who is sponsoring clinical trial NCT00691197?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00691197 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ametropia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
North American Comfilcon A Clinical Study
RECRUITING
-
Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol
RECRUITING · NA
-
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
COMPLETED · NA
-
Apioc Contact Lens Feasibility
COMPLETED · NA
-
Evaluation of Monthly Replacement Lenses in Habitual Soft Contact Lens Wearers Who Report Frequent Digital Devise Use
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.